Home

Insights

Kopran Ltd P/E Ratio

Kopran Ltd P/E Ratio

download
stocks purchased

₹ 2.0 Cr

Volume transacted

stocks purchased

75.8 K

stocks traded

Image

Kopran Ltd

NSE: KOPRAN

PE

21.3

Last updated : 13 Jun 15:30 pm

Key Highlights

    The P/E Ratio of Kopran Ltd is 21.3 as of 13 Jun 15:30 pm .a1#The P/E Ratio of Kopran Ltd changed from 7.5 on March 2019 to 19.5 on March 2023 . This represents a CAGR of 21.06% over 5 years. a1#The Latest Trading Price of Kopran Ltd is ₹ 259.75 as of 13 Jun 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 21.7. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 102.9. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Kopran Ltd changed from ₹ 179.93 crore on March 2019 to ₹ 532.49 crore on March 2023 . This represents a CAGR of 24.23% over 5 years. a1#The Revenue of Kopran Ltd changed from ₹ 126.27 crore to ₹ 195.75 crore over 8 quarters. This represents a CAGR of 24.51% a1#The EBITDA of Kopran Ltd changed from ₹ 13.8 crore to ₹ 31.36 crore over 8 quarters. This represents a CAGR of 50.75% a1#The Net Profit of Kopran Ltd changed from ₹ 7.6 crore to ₹ 18.62 crore over 8 quarters. This represents a CAGR of 56.52% a1#The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2019 to 46.28 % on March 2023 . This represents a CAGR of -5.75% over 3 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '197.5
Mar '205.2
Mar '217.4
Mar '2222.2
Mar '2319.5

Fundamental Metrics

Market Cap

1,252 Cr

EPS

10.6

P/E Ratio (TTM) *

21.3

P/B Ratio (TTM) *

2.2

Day’s High

262.0

Day’s Low

238.95

DTE *

0.2

ROE *

10.4

52 Week High

292.4

52 Week Low

160.0

ROCE *

12.9

* All values are consolidated

* All values are consolidated

Image

Kopran Ltd

NSE: KOPRAN

PRICE

259.75

21.05 (8.82%)

stock direction

Last updated : 13 Jun 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value

Market Value

1,087

Asset Value

402

1.7 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

50 Cr

21.3 X

PE Ratio

Market Cap

₹1086Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

50 Cr

21.3 X

PE Ratio

Market Cap

₹1086Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Kopran Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Kopran Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Kopran Ltd's Share Price stands at 259.75. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-06-13T00:00:00 is 10.57. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 259.75/ 10.57= 21.33.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Kopran Ltd's stock is trading at approximately 21.33 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Kopran Ltd’s PE Ratio (BSE: KOPRAN)

    The Price-to-Earnings (PE) ratio, used to assess Kopran Ltd's stock (BSE: KOPRAN), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '19180
Mar '20110
Mar '21454
Mar '221357
Mar '23532

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22126
Sep '22117
Dec '22160
Mar '22153
Jun '23119
Sep '23153
Dec '23161
Mar '23196

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2214
Sep '2211
Dec '2215
Mar '2216
Jun '239
Sep '2323
Dec '2326
Mar '2331

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '228
Sep '225
Dec '227
Mar '228
Jun '233
Sep '2314
Dec '2316
Mar '2319

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '190
Mar '200
Mar '2155
Mar '22123
Mar '2346

* All values are a in %

About Kopran Ltd

About Kopran Ltd

    Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004. Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.

Kopran Ltd News Hub

News

Kopran schedules AGM

Kopran announced that the 65th Annual General Meeting(AGM) of the company will be held on ...

Read more

16 May 202416:32

News

Board of Kopran recommends Final Dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 16 May ...

Read more

16 May 202414:23

News

Kopran to announce Quarterly Result

Kopran will hold a meeting of the Board of Directors of the Company on 16 May 2024 Powered...

Read more

08 May 202416:09

News

Kopran to announce Quarterly Result

Kopran will hold a meeting of the Board of Directors of the Company on 7 February 2024. Po...

Read more

23 Jan 202416:22

News

Kopran to conduct board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 7 November 2023. Po...

Read more

27 Oct 202316:52

News

Kopran to conduct AGM

Kopran announced that the Annual General Meeting (AGM) of the company will be held on 14 S...

Read more

19 Aug 202311:51

Product Composition by Percentage (Revenue)

FAQs for PE of Kopran Ltd

What is Kopran Ltd current share price?

The current market price of Kopran Ltd as of June 13, 2024 is ₹259.75.

What is Kopran Ltd's market cap?

Kopran Ltd's market capitalisation stood at ₹1,086 Cr as of June 13, 2024

What are Kopran Ltd's total net assets?

According to Kopran Ltd's most recent financial filings, the company's net assets total ₹401.8 Cr.

Is Kopran Ltd making a profit or loss?

Kopran Ltd's net Profit as of June 13, 2024 is close to ₹50 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199